{"entity":{"id":"montefiore-einstein","kind":"institution","name":"Montefiore Einstein Comprehensive Cancer Center","aka":["Albert Einstein Cancer Center"],"tldr":"The Bronx's NCI comprehensive cancer centre, where Joseph Sparano ran TAILORx, the trial that let most women with early HR-positive breast cancer skip chemotherapy.","summary":"The Albert Einstein Cancer Center has been NCI-designated since 1972 and, as Montefiore Einstein Comprehensive Cancer Center, now holds comprehensive status while serving one of the poorest urban counties in the United States. Joseph Sparano chaired TAILORx from here for ECOG-ACRIN, showing that a mid-range Oncotype DX recurrence score identifies women who do not need adjuvant chemotherapy. John Condeelis's intravital imaging revealed the TMEM 'doorways' through which breast cancer cells enter the bloodstream; Ulrich Steidl and Amit Verma lead work on MDS and leukaemia stem cells. Director Edward Chu is a GI oncologist and cancer pharmacologist.","asOf":"2026-09-09","links":[{"label":"Montefiore Einstein Comprehensive Cancer Center","url":"https://montefioreeinstein.org/cancer"},{"label":"Clinical trials","url":"https://montefioreeinstein.org/cancer/research/clinical-trials"}],"tags":[],"related":[],"cancers":["breast-hr-positive","mds","aml"],"sections":[],"technologies":["optical-imaging"],"targets":[],"drugs":["oncotype-dx"],"companies":["ecog-acrin"],"institutions":[],"pathways":[],"terms":[],"trials":["tailorx"],"people":["ulrich-steidl"],"bottlenecks":["b-metastasis-biology","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bronx, NY","country":"US","lat":40.88,"lng":-73.879,"institutionType":"cancer-center","website":"https://montefioreeinstein.org/cancer","nci":"comprehensive","university":"Albert Einstein College of Medicine","programs":["Breast cancer (TAILORx)","Metastasis imaging","MDS and leukaemia stem cells","Bronx community oncology"]},"route":"/institutions/montefiore-einstein/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"technology":[{"id":"optical-imaging","kind":"technology","name":"Optical & fluorescence imaging","route":"/technologies/optical-imaging/"}],"drug":[{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/"}],"company":[{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/"}],"trial":[{"id":"tailorx","kind":"trial","name":"TAILORx","route":"/trials/tailorx/"}],"person":[{"id":"ulrich-steidl","kind":"person","name":"Ulrich G. Steidl","route":"/people/ulrich-steidl/"}],"bottleneck":[{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"new-york-proton-center","kind":"institution","name":"New York Proton Center","route":"/institutions/new-york-proton-center/"}],"collection":[{"id":"nci-cancer-centers","kind":"collection","name":"NCI-Designated Cancer Centers","route":"/collections/nci-cancer-centers/"}]}}